US2007010575A1PendingUtilityA1

Intracorporeal medicaments for photodynamic treatment of disease

61
Assignee: XANTECH PHARMACEUTICALS INCPriority: Oct 30, 1996Filed: Sep 15, 2006Published: Jan 11, 2007
Est. expiryOct 30, 2016(expired)· nominal 20-yr term from priority
A61P 9/00A61P 31/04A61P 41/00A61P 43/00A61P 31/12A61P 35/00A61P 31/10A61P 31/00A61P 5/00A61P 33/00A61P 17/06A61N 5/062A61K 41/0071A61K 49/0041A61P 17/00A61N 5/0601Y10T436/153333A61K 41/0057A61K 41/0038A61K 47/20A61P 1/04C07D 311/82A61P 11/00A61B 2017/22062Y10T436/19Y10T436/193333A61P 13/00A61B 2017/00057A61K 47/12A61P 1/00A61P 15/00A61K 41/008A61P 13/02A61F 7/00A61B 2017/22087A61K 49/0433A61K 9/0019A61K 47/10A61K 31/352A61K 31/35Y02A50/30
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

Claims

exact text as granted — not AI-modified
1 - 44 . (canceled)  
     
     
         45 . A method comprising: 
 providing a halogenated xanthene selected from the group consisting of Erythrosin B, Phloxine B, and Rose Bengal in a dosage form suitable for use as a medicament for intravenous, intramuscular, intratumoral or transcutaneous delivery; and    providing instructions to use said medicament for photodynamic treatment of diseased human tissue, said diseased human tissue comprising cancerous or pre-cancerous lesions, dermatologic disease, or bacterial infection, using light applied to said diseased human tissue at an intensity of 200 mW/cm 2  or less.    
     
     
         46 . A method comprising: 
 providing a halogenated xanthene selected from the group consisting of Erythrosin B, Phloxine B, and Rose Bengal in a dosage form suitable for use as a medicament for per oesophageal or intracavitary administration; and    providing instructions to use said medicament for photodynamic treatment of diseased human tissue, said diseased human tissue comprising cancerous or pre-cancerous lesions, dermatologic disease, or bacterial infection, using light applied to said diseased human tissue at an intensity of 200 mW/cm 2  or less.    
     
     
         47 . A method of treating cancerous or pre-cancerous lesions, dermatologic disease, or bacterial infection of human tissue comprising: 
 providing a dosage unit of a sterile intracorporeal photodynamic medicament consisting of an aqueous solution of a sodium, potassium or lithium salt of a halogenated xanthene, wherein said halogenated xanthene is a compound selected from the group consisting of Erythrosin B, Phloxine B, and Rose Bengal; and    providing instructions for use of said medicament for photodynamic treatment of said diseased human tissue using light applied to said diseased human tissue at an intensity of 200 mW/cm 2  or less.    
     
     
         48 . A method of treating cancerous or pre-cancerous lesions, dermatologic disease, or bacterial infection of human tissue comprising: 
 providing a dosage unit of an intracorporeal photodynamic medicament consisting of a capsule, a suppository, a syrup, or a micro-droplet spray containing a halogenated xanthene, wherein said halogenated xanthene is a compound selected from the group consisting of Erythrosin B, Phloxine B, and Rose Bengal; and    providing instructions for use of said medicament for photodynamic treatment of said diseased human tissue using light applied to said diseased human tissue at an intensity of 200 mW/cm 2  or less.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.